source
- Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and moreWelcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t already, check out Ma…Endpoints · 1mo ago↗ source
- At ASCO, Merck makes case for a ‘cornerstone’ cancer drugStudy results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.BioPharma Dive · 2mo ago↗ source
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.